Have got full advance for 110 mn doses, says Serum CEO Poonawalla

Poonawalla, who left for the UK recently, said in an interview that he was getting threatening calls from powerful people in India for delivering vaccine

Adar Poonawalla, CEO, Serum Institute
Adar Poonawalla, CEO, Serum Institute
Sohini Das Mumbai
2 min read Last Updated : May 04 2021 | 7:16 AM IST
Pune-based vaccine maker Serum Institute of India will supply 220 million doses to the Centre, state governments and private hospitals in the next few months, according to the latest numbers given out by the company.

In a statement, Adar Poonawalla, CEO of SII, said on Monday that the firm had received total orders of 260 million doses from the government. Out of that, more than 150 million doses have been supplied. “We have also got 100 percent advance of Rs 1,732.5 crore for the next tranche of 110 million doses in the next few months,” he said. 

In addition, another 110 million doses will be supplied to state governments and private hospitals in the next few months, making it a total of 220 million. In an interview to a news channel on April 21, Poonawalla had said, “This fresh 110 million doses contract was agreed upon about a month ago and so we are starting to supply that from this month.” 

He was speaking in the context of the future price to the Centre and state governments.

Poonawalla, who left for the UK recently, said in an interview that he was getting threatening calls from powerful people in India for delivering vaccine.      

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusSerum Institute of IndiaCoronavirus Vaccine

Next Story